Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2019 February;38(1) > International Angiology 2019 February;38(1):17-21

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE  VENOUS DISEASE Freefree

International Angiology 2019 February;38(1):17-21

DOI: 10.23736/S0392-9590.18.04031-2

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Treatment of deep vein thrombosis with rivaroxaban and its potential to prevent the post-thrombotic syndrome

Pier Luigi ANTIGNANI 1 , Claudio ALLEGRA 2, Jawed FAREED 3

1 Vascular Center, Nuova Villa Claudia, Rome, Italy; 2 Central European Vascular Forum, Praha, Czech Republic; 3 Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, IL, USA



BACKGROUND: The study was initiated following the observation of complete recanalization of thrombus in subjects with DVT treated with rivaroxaban after 1-2 weeks. The aim of this observational retrospective study was to evaluate clinically and by means of echo color Duplex, the fibrinolytic effect of rivaroxaban in patients with recent and previous DVT. To accomplish this two populations of patients were evaluated.
METHODS: Group 1 was comprised of 31 patients (ranging in age 52-73 years) with popliteal-femoral DVT (12 months ago) treated with standard anticoagulant therapy. In these patients, we found a complete superficial femoral recanalization and partial recanalization of the popliteal vein (30% of residual thrombus). The patients had normal creatinine clearance and liver function. The patients were switched from warfarin to rivaroxaban due to a lack of compliance with warfarin therapy. Group 2 was comprised of 22 patients (ranging in age 65-82 years) with previous popliteal-femoral DVT and documented complete common femoral veins recanalization who presented with a recent superficial femoral vein re-thrombosis (1 week before). The patients had normal creatinine clearance and liver function. The patients switched from warfarin to rivaroxaban due to a lack of compliance with warfarin therapy.
RESULTS: In group 1, all patients exhibited the complete recanalization of the popliteal veins after 4 weeks of rivaroxaban therapy. In group 2, all patients exhibited the complete recanalization of the popliteal veins after 4 weeks, and the complete recanalization of the acute re-thrombosis of the superficial femoral veins after 2 weeks of rivaroxaban therapy. No adverse events for both groups were observed.
CONCLUSIONS: Our results suggest that rivaroxaban could have a pro-fibrinolytic effect not only on recent thrombus but also on organized thrombus that results in a complete recanalization of affected veins. It is proposed that this lytic effect will preserve venous valve structure and lead to a reduction of incidence of post-thrombotic syndrome in rivaroxaban treated patients.


KEY WORDS: Deep venous thrombosis - Rivaroxaban - Post-thrombotic syndrome

inizio pagina